E&G Advisors LP Has $1.35 Million Stock Holdings in Merck & Co., Inc. (NYSE:MRK)

E&G Advisors LP trimmed its holdings in shares of Merck & Co., Inc. (NYSE:MRK) by 3.6% in the second quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 16,139 shares of the company’s stock after selling 597 shares during the period. E&G Advisors LP’s holdings in Merck & Co., Inc. were worth $1,353,000 at the end of the most recent quarter.

Several other institutional investors have also bought and sold shares of the company. PRW Wealth Management LLC acquired a new stake in Merck & Co., Inc. in the 4th quarter valued at about $41,000. Aspire Private Capital LLC acquired a new stake in Merck & Co., Inc. in the 4th quarter valued at about $55,000. Thor Advisors LLC acquired a new stake in Merck & Co., Inc. in the 1st quarter valued at about $69,000. Contravisory Investment Management Inc. lifted its stake in Merck & Co., Inc. by 19.7% in the 2nd quarter. Contravisory Investment Management Inc. now owns 858 shares of the company’s stock valued at $72,000 after purchasing an additional 141 shares during the last quarter. Finally, Mark Sheptoff Financial Planning LLC lifted its stake in Merck & Co., Inc. by 150.0% in the 4th quarter. Mark Sheptoff Financial Planning LLC now owns 1,000 shares of the company’s stock valued at $76,000 after purchasing an additional 600 shares during the last quarter. Institutional investors own 75.15% of the company’s stock.

In other news, CFO Robert M. Davis sold 216,718 shares of the firm’s stock in a transaction that occurred on Tuesday, June 25th. The shares were sold at an average price of $85.43, for a total transaction of $18,514,218.74. Following the transaction, the chief financial officer now directly owns 354,378 shares of the company’s stock, valued at $30,274,512.54. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, EVP Frank Clyburn sold 25,000 shares of the firm’s stock in a transaction that occurred on Tuesday, May 7th. The stock was sold at an average price of $77.73, for a total transaction of $1,943,250.00. Following the transaction, the executive vice president now directly owns 92,604 shares in the company, valued at $7,198,108.92. The disclosure for this sale can be found here. 0.27% of the stock is currently owned by company insiders.

Several brokerages recently issued reports on MRK. ValuEngine downgraded shares of Merck & Co., Inc. from a “buy” rating to a “hold” rating in a research note on Thursday. Mizuho began coverage on shares of Merck & Co., Inc. in a research note on Tuesday, July 2nd. They issued a “buy” rating and a $97.00 target price for the company. Goldman Sachs Group began coverage on shares of Merck & Co., Inc. in a research note on Tuesday, May 28th. They issued a “neutral” rating and a $85.00 target price for the company. Credit Suisse Group began coverage on shares of Merck & Co., Inc. in a research note on Thursday, July 11th. They issued a “buy” rating and a $95.00 target price for the company. Finally, Bank of America set a $97.00 target price on shares of Merck & Co., Inc. and gave the company a “buy” rating in a research note on Thursday, July 11th. Three investment analysts have rated the stock with a hold rating and fifteen have given a buy rating to the stock. The stock has an average rating of “Buy” and an average price target of $90.36.

Shares of MRK opened at $83.69 on Friday. Merck & Co., Inc. has a 12 month low of $64.87 and a 12 month high of $87.07. The stock’s 50 day simple moving average is $83.17. The company has a market capitalization of $214.39 billion, a PE ratio of 18.46, a PEG ratio of 1.72 and a beta of 0.57. The company has a debt-to-equity ratio of 0.82, a current ratio of 1.37 and a quick ratio of 1.06.

Merck & Co., Inc. (NYSE:MRK) last announced its earnings results on Tuesday, July 30th. The company reported $1.30 EPS for the quarter, topping the Thomson Reuters’ consensus estimate of $1.16 by $0.14. Merck & Co., Inc. had a net margin of 21.10% and a return on equity of 40.39%. The company had revenue of $11.76 billion for the quarter, compared to analysts’ expectations of $10.94 billion. During the same period last year, the firm earned $1.06 earnings per share. The business’s revenue for the quarter was up 12.4% on a year-over-year basis. As a group, sell-side analysts forecast that Merck & Co., Inc. will post 4.93 EPS for the current year.

The firm also recently announced a quarterly dividend, which will be paid on Monday, October 7th. Stockholders of record on Monday, September 16th will be issued a dividend of $0.55 per share. The ex-dividend date of this dividend is Friday, September 13th. This represents a $2.20 annualized dividend and a dividend yield of 2.63%. Merck & Co., Inc.’s dividend payout ratio is presently 50.69%.

Merck & Co., Inc. Profile

Merck & Co, Inc provides healthcare solutions worldwide. It operates through four segments: Pharmaceutical, Animal Health, Healthcare Services, and Alliances. The company offers therapeutic and preventive agents to treat cardiovascular, type 2 diabetes, chronic hepatitis C virus, HIV-1 infection, intra-abdominal, fungal infection, insomnia, and inflammatory diseases.

Featured Article: What is Net Asset Value (NAV)?

Want to see what other hedge funds are holding MRK? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Merck & Co., Inc. (NYSE:MRK).

Institutional Ownership by Quarter for Merck & Co., Inc. (NYSE:MRK)